The pill, Rybelsus, barely works. They've having to put 700%+ more than the injections to still get a lower overall effectiveness. They're actively working on alternative delivery methods to resolve this.
A daily pill GLP-1 will be a massive commercial success. Rybelsus isn't very good for either the manufacturer or the consumer. You're burning a lot of expensive peptide to get a worse outcome at every dose level.
An efficient drug delivery mechanism you can’t get into the hands of a broad population cohort is not efficient. We are optimizing for accessibility for everyone who needs access to this drug family (imho).
At some point it isn't "perfect Vs. good" it is "effective Vs. ineffective." Rybelsus is an ineffective medication. Even with the eye watering waste set out above, it is reported as being less effective as a GLP-1 too. There is no upside.
A pill GLP-1 is an absolute game-changer. We just aren't there yet.